vTv Therapeutics to Participate in Upcoming September Investor Conferences

Company Overview - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes [1][2] - The company is also investigating multiple molecules across different indications for chronic diseases [2] Upcoming Investor Conferences - vTv Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with a format of 1x1 investor meetings only [1] - The company will also be present at the Morgan Stanley 23rd Annual Global Healthcare Conference on the same day, featuring a fireside chat from 2:35 PM to 3:10 PM EST, along with 1x1 investor meetings [2] Clinical Pipeline - The clinical pipeline of vTv is led by cadisegliatin, which is currently in a Phase 3 trial for type 1 diabetes [2]